Human T cell leukemia/lymphoma virus type I infection of a CD4+ proliferative/cytotoxic T cell clone progresses in at least two distinct phases based on changes in function and phenotype of the infected cells.
The effect of human T cell leukemia/lymphoma virus type I (HTLV-I) infection on the function and the phenotype of a human proliferating/cytotoxic T cell clone, specific for tetanus toxin, was investigated. During the period after infection, two distinct phases were observed, based on growth properties, phenotype, and functional activity of the infected cells. Phase I HTLV-I infected cells (0 to about 150 days after infection) proliferated in an IL-2-dependent way, but without the requirement for repetitive antigenic stimulation. No differences in expression of the CD2, CD3, CD4, Tp103, and CD28 Ag between these cells and the parental cells could be demonstrated, with the exception of the expression of IL-R p55 and HLA-DR Ag, which were constitutively expressed on the phase I cells. The phase I HTLV-I-infected cells, as well as the parental 827 cells reacted with a mAb specific for an epitope on the variable part of the TCR beta-chain, indicating that the TCR was not altered after HTLV-I infection. Like the parental clone, the phase I cells proliferated in response to tetanus toxin, but the tetanus toxin-specific response of the phase I cells did not require the presence of APC. Results of experiments, in which the levels of intracellular Ca2+ were measured, indicated that HTLV-I cells can acquire the capability to process Ag and present that to themselves. Phase I HTLV-I-infected T cells had lost their cytotoxic activity which was likely to be due to an effect on the lytic machinery rather than on Ag recognition by the TCR, inasmuch as it was found that phase I HTLV-I-infected T cells did no longer contain N-alpha-benzyloxy-L-lysine thiobenzylester-serine esterase activity. Furthermore, it was found that phase I HTLV-I-infected T cells had a diminished capacity to form conjugates with target cells. From a period of about 200 days after HTLV-I infection, phase II cells emerged that proliferated strongly in the absence of IL-2 and that had lost all functional activity. These cells did not express the CD3/T cell receptor complex on their surface. Phase I as well as phase II HTLV-I-infected cells were targets for CTL raised in the autologous donor.
Yssel
H
H
UNICET, Laboratory for Immunological Research, Dardilly, France.
de Waal Malefyt
R
R
Duc Dodon
M D
MD
Blanchard
D
D
Gazzolo
L
L
de Vries
J E
JE
Spits
H
H
D000938:Antigen-Presenting Cells / Q000276:immunology; D000945:Antigens, Differentiation, T-Lymphocyte; D002455:Cell Division; D002999:Clone Cells / Q000145:classification* / Q000276:immunology / Q000378:metabolism; D003601:Cytotoxicity Tests, Immunologic; D000939:Epitopes / Q000276:immunology; D015329:Gene Rearrangement, T-Lymphocyte; D015490:HTLV-I Infections / Q000235:genetics / Q000276:immunology*; D006801:Humans; D008213:Lymphocyte Activation; D010641:Phenotype; D013602:T-Lymphocytes, Cytotoxic / Q000145:classification* / Q000276:immunology / Q000378:metabolism; D013744:Tetanus Toxin / Q000276:immunology
D000945:Antigens, Differentiation, T-Lymphocyte; D000939:Epitopes; D013744:Tetanus Toxin